INTERNATIONAL & USA PRESS INQUIRIES
Please contact David Fraser for international media inquiries
Please contact Corey Henry for USA media inquiries
May 24, 2019
Philip Morris International Releases Latest Scientific Update for Smoke-Free Products on Clinical Program
An In-Depth Look at How Good Clinical Practices Ensure Ethical Conduct
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171212005891/en/
Philip Morris International Releases Latest Scientific Update for Smoke-Free Products on Clinical Program (Photo: Business Wire)
This issue of the Scientific Update provides a closer look at
some of the principles and practices on which PMI’s scientific
assessment program is built. Director Medical Affairs Dr.
Picavet stated, “The performance of clinical studies is a complicated process. Strict implementation of Good Clinical Practices is particularly important to assure the quality and consistency of the research and to address unexpected events that can occur during a study. These Practices are key to the validity of data and the safety of study participants.”
Beyond recent events and publications, this issue also describes PMI’s progress towards sharing all raw data from studies on IQOS in part through the new data-sharing platform called INTERVALS.
PMI’s extensive research and assessment program is inspired by the
well-recognized practices of the pharmaceutical industry and in line
with the draft guidance of the U.S.
Philip Morris International Inc. (PMI) is a leading international tobacco company, with six of the world's top 15 international brands and products sold in more than 180 markets. In addition to the manufacture and sale of cigarettes, including Marlboro, the number one global cigarette brand, and other tobacco products, PMI is engaged in the development and commercialization of reduced-risk products (RRPs). RRPs is the term PMI uses to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continued smoking. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and industry-leading scientific substantiation, PMI aims to provide an RRP portfolio that meets a broad spectrum of adult smoker preferences and rigorous regulatory requirements. For more information, see our PMI and PMI Science websites.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171212005891/en/
Philip Morris International media office
T: +41 (0)58 242 4500